Member Info for fundraiser222

If q4 results are no good, very risky place to do business and it doesnt look like their business model is working very well at present, mcap looks high given all the issues and poor management in a risky country

No chance of 6-7p the license is in some of the deepest and most expensive waters on earth and thy don’t have 3d seismic or a farm in and have a useless ceo who takes £300k plus a year for doing naff all, 3p is realistic if the CPR is any good, when it comes is anyone’s guess these guys don’t stick to timescales and don’t give a dam about private investors or the share price all imo

What’s the issue here maestro? You seem very angrey at the investors in gbp.... maybe it’s because we are in at 2p and you resent the fact we will make cash when CPR comes out and we sell for a nice juicy profit? Don’t worry I will sell you mine for 3p or you can buy now at 2.30p your choice old boy or just sit back and watch the spike, all the best for 2018

20% dilution after this ridiculously low placing at 12p, and the ceo only wants to take a tiny 40k shares... just about sums it up really. Very disappointed and I would not be surprised to see this slip below 10p imo over the next few months

Couldn’t be much worst this morning imo very disappointing they havnt made hardly any progress only 18 patients recruited out of 60 target and 34 out of 90 target is well below what I was expecting and is not much progress at all from the update 5 months ago, no wonder they had to raise at such a huge discount, what a shame

Not happy at all with the placing price of 12p this is imo going to create a huge overhang unfortunately going to be a blood bath here today I think not happy at all

To see the share price crashing again back down towards 14/15p zone where it seems to settle. I feel Evgen need to get this funding issue sorted ASAP as ceo Stephen franklin said himself in June that they need to start looking at strengthening the balance sheet so I assume raising some funds is now imminent due to the need for extra cash to finish the trials in late 2018, hopefully any placing that may happen won’t be at a huge discount and after any placing the share price can move forward instead of continuing to fall back, all imo disappointing day and low volume

No problem if it was a mistake due to lack of research I thought you were deliberately misleading. Full readout of trials got delayed until the end of 2018 unfortunately if you read the agm statement on the website, and yes the SAS trial if positive has the potential to come to market in let’s say 2020 imo given the near 12 month delay whilst doing phase 3 trials at the same time. I am hopeful they will raise funds soon so we can get it out of the way as feel it is holding back the share price as investors hate the thought of a discounted placing

That interview is not a current interview it is years old! Please read the agm statement and the final results this year 2017 they both state full readout of trials will be towards the end of 2018 and they only have enough cash left until spring 2018, you have to state the current state of play as deadlines get delayed unfortunately, I just don’t want investors to be mislead on the facts as it will only lead to disappointment and a crashing price when ppl research for themselves like you should have done

I have to say Shan I am very disappointed with your statements tonight, these sort of lies will only lead to disappointment when ppl read in the half yearly report that full readout from both trials is not due until the end of 2018, I have no idea where you have got January from or why you say product will be on the shelves by 2019, they need to do phase 3 trials after phase two trials. Be careful what you write on these boards as giving false information as fact is illegal and in this case very very misleading

I’m sorry Shan but you have got both those statements very wrong indeed I’m afraid to say. Results for both the trials are not due until late 2018 please see the agm statement and the final results report. They both state that readout from both trials will be towards the end of 2018. Due to this they DO need extra funds to complete the trials they have approx £300k a month cash burn and will only have enough cash to last until spring 2018 so extra cash will be needed. I am all for been positive and sharing research but we cannot tell lies, please listen and read the final results full readout from trials end of 2018

It fall below 20p again after a good rise, I can only assume the sellers are worried about the placing but when/If it comes it shouldn’t be for a huge amount dilution will hopefully be minimal and then we can look forward. The need for more funds is certainly the elephant in the room atm unfortunately

Since this mornings early flurry of buys followed by a flurry of sells. Very volatile in both directions due to the low free float, hopefully we can hold the gains this time and hold 20p

Which I guess is a good sign as there are no posters and the price continues to rise on consistent buying, we saw what happens when the herd arrive two weeks ago it shot to 29p in 2 hours! When the half year report lands and the herd arrive again on positive news I expect this to bag very quickly and think any rise will be sustained as the interim breast cancer trial readout could Imo come soon after the half yearly report and if that gives a positive readout we should soar towards 90p given the potential for SFX-01 to be used in multiple cancer types, and multiple disease types all with multi billion dollar revenue potential markets. Don’t forget before Evgen listed at 37p two years ago they were approached for a buyout and that was before the phase two trials had even begun! Before patents in USA and Europe the two biggest markets, before orphan drug designation was granted in the USA, and before the breast cancer trial granted a compassionate use program with the first ever patient dosed having no tumour growth over 24 weeks, so much good news since they lost d yet the price is 50% below ipo price very undervalued imo dyor

$6bn market revenue opportunity for the two current phase 2 trials with the SAS trial already been granted orphan drug designation. SFX-01 also has the opportunity to be used in Austism, MS, arthritis and lots of different cancers... so from a £12m mcap and broker target of 97p I cannot see a better share on aim for blue sky multibag potential for 2018. Short term catalysts with half yearly results due in next few weeks with full trial update imo Q1 breast cancer interim trial readout will multibag it alone if positive. A transformational few months ahead staggering potential that’s for sure With the breast cancer trial already granting a compassionate use program to the first patient dosed with SFX-01 who showed no disease progression after 6 months and 3 scans of using the drug..... good luck all an exciting few weeks and months ahead imo dyor the rise a few weeks ago was a nice warm up for the main event and shows how quickly this will move on news imo

The fact the first patient in the breast cancer trial had no disease progression after 6 months and 3 scans and a compassionate use program was activated is very good news and I am looking forward to hearing more of the compassionate use program and how many patients are on it Etc hopefully in the half yearly report

Still here with some consistent buying and hardly any sells which suggests to me this goes higher over the coming days as we await the half yearly report. It was out on the 5th December last year and the 7th December in 2015 so perhaps they may go for the middle this year and release news on the 6th tomorrow? Either way news will come imminently at a very exciting time for the pharma sector

Which is great and suggests as this becomes on more ppls radar the price may be heading for a strong rise just has VAL has over the last few days. 20% a day is far better than a large spike to 29p as we saw 2 weeks ago here as it creates a new base as we await news due any day now. As more people begin to fully research the potential and the pharma sector hot we could be looking at a perfect storm for Evg to release a cracker of an rns, the ceo audio presentation on the website is well worth a listen and note towards the end he states that he is in active dialogue with potential partners.... all imo dyor

Yes half year report has been released in the first week of December in the last two years and as we know with pharma stocks positive news sends it crazy especially so with evg with hardly any shares available

Steady rise for a few days then shoot up, it’s completely under the radar but when the herd arrive the rise can be explosive as we saw a couple of weeks ago when it hit 29p in no news, when the half yearly report lands this could go crazy if positive on the trials imo huge potential imo dyor